SECUKINUMAB DRUG SURVIVAL IN PSORIASIS AND PSORIATIC ARTHRITIS PATIENTS: A 24-MONTH REAL-LIFE STUDY
- Augusta Ortolan (Italy)
Abstract
Background and Aims
Secukinumab effectiveness has been demonstrated in both psoriasis (PsO) and psoriatic arthritis (PsA). However, it is unknown whether arthritis, compared to PsO alone, may represent a risk factor for withdrawal. Our aim was to identify predictors of secukinumab survival, including the presence of arthritis, in PsO and PsA.
Methods
Consecutive PsO and PsA patients initiating secukinumab were enrolled and followed-up every 6 months, up to 24-months or discontinuation. Medical history, disease activity indices and Body Mass Index (BMI) were collected. Kaplan-Meier curves and log-rank test were used to analyze differences in drug survival according to sex, BMI, biological therapy line in the whole population (psoriatic disease) and separately for PsO/PsA. A multivariable Cox-regression model was built to assess whether presence of arthritis (main independent variable) may influence drug survival by having time-to-secukinumb-discontinuation as outcome. Results were expressed as Hazard Ratio (HR) and 95% Confidence Interval (95%CI).
Results
Sixty-two PsO and 90 PsA patients were enrolled (Table). Retention rate was 77% and 59% at 12- and 24-months. In the whole population, naïve patients displayed higher drug survival (log-rank=4.06; p=0.04); in PsA, obese patients were more likely to discontinue secukinumab (log-rank=5.25; p=0.021). The multivariable Cox-regression showed that arthritis was independently associated with a higher risk of secukinumab discontinuation (HR 2.43; 95%CI:1.06-5.55, p=0.035) after adjusting for age, sex, gender, BMI, therapy line and PsO severity at baseline.
Conclusions
Our data confirmed a good response to secukinumab in both PsO and PsA patients. However, presence of arthritis might affect drug survival.